Report Back From ASCO 2024: What’s the Latest in HR+ MBC?
Today, we’re bringing you a very special episode created in partnership with SHARE Cancer Support. This is an audio version of our webinar “Report Back from ASCO 2024: Latest Updates on Metastatic Breast Cancer (MBC)”.
We're excited to present this report from the 2024 ASCO Annual Meeting, highlighting the latest advancements and research in hormone receptor positive (HR+) metastatic breast cancer. ASCO, the American Society of Clinical Oncology, is a leading organization in the cancer field, and their annual meeting is a crucial event for unveiling groundbreaking research and new treatment options. Attending the congress always amazes us with the sheer number of attendees and the engaging discussions about the newest research and treatments. The poster sessions are particularly eye-opening, showcasing innovation and inspiring hope for future treatments and better side effect management.
In today's episode, you will hear from Dr. Kevin Kalinsky, a medical oncologist and investigator from Emory. We will dive deep into the findings from the DESTINY-Breast06 trial and the postMONARCH trial. We'll explore the implications of these studies, how they could impact treatment strategies, and what this means for us.
Join us as we unpack the key takeaways for HR+ MBC from ASCO 2024.
Meet the Guest of the Episode
Kevin Kalinsky, MD, MS
Dr. Kalinsky is Associate Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. He serves as the director of the Glenn Family Breast Center at Winship where he is tasked with fulfilling the vision to improve breast cancer outcomes by aligning research and education with cancer treatment and prevention. Dr. Kalinsky received his medical degree from the Medical University of South Carolina and a Masters in Biostatistics, Patient Oriented Research Track from Columbia University Mailman School of Public Health. His training included a Residency and Medical Oncology Fellowship at Tufts-New England Medical Center, Breast Cancer Research Fellowship at Massachusetts General Hospital, and Breast Cancer Advanced Oncology Fellowship at Memorial Sloan-Kettering Cancer Center. Dr. Kalinsky's research involves the development of early-phase clinical trials to assess novel therapeutics in breast cancer based on tumor genomics. He has received the NCI Cancer Clinical Investigator Team Leadership Award, Physician of Impact Award by Komen Greater NYC, Ewig Clinical Scholar Teaching Award, and SWOG Career Engagement Award
Twitter: @KalinskyKevin
